ストックスクリーナーアプリを入手
38.53
0.60%
0.2844
Harmony Biosciences Holdings Inc (HRMY) 最新ニュース
Capital Fund Management S.A. Invests $1.14 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
How supply chain issues affect Harmony Biosciences Holdings Inc. stockDividend Hike & Smart Allocation Stock Reports - Newser
How analysts rate Harmony Biosciences Holdings Inc. stock today2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com Nigeria
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Biosciences to present Dravet syndrome trial data at AES meeting - Investing.com Canada
Harmony Biosciences Valuation Outlook After Recent Share Price Rebound - Yahoo Finance UK
How Pitolisant GR Progress and New Orexin Agonist Will Impact Harmony Biosciences (HRMY) Investors - Yahoo Finance
Harmony Biosciences (HRMY): Reassessing Valuation After Positive Pitolisant Study and New Orexin 2 Agonist Trial - Yahoo Finance
A Look at Harmony Biosciences (HRMY) Valuation Following Key Pipeline Advancements and Positive Trial Results - simplywall.st
Harmony Biosciences to present Dravet syndrome trial data at AES meeting By Investing.com - Investing.com South Africa
Harmony Biosciences (Nasdaq: HRMY) to share new EPX-100 Dravet data at 2025 AES - Stock Titan
Prudential Financial Inc. Has $4.79 Million Stake in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc Stock Analysis and ForecastPrice Momentum Alerts & Fast Growing Capital Gains - earlytimes.in
Mizuho Maintains Harmony Biosciences Holdings (HRMY) Outperform Recommendation - Nasdaq
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress By Investing.com - Investing.com South Africa
Harmony Biosciences Launches Early Trial of Promising Orexin Agonist - MSN
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress - Investing.com Australia
HRMY Upgraded by Mizuho: Price Target Raised to $46 | HRMY Stock News - GuruFocus
Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating - marketscreener.com
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $46 at Mizuho - StreetInsider
Harmony Biosciences appoints Adam Zaeske as Chief Commercial Officer - MSN
Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences - MyChesCo
Geode Capital Management LLC Raises Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
(HRMY) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can Harmony Biosciences Holdings Inc. stock deliver surprise earnings beatEarnings Overview Summary & Verified Swing Trading Watchlist - BỘ NỘI VỤ
SG Americas Securities LLC Sells 15,390 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Jefferies Financial Group Inc. Purchases 26,326 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright on positive study results - Investing.com Canada
Harmony Biosciences stock reaffirmed at Outperform by Oppenheimer - Investing.com Canada
HC Wainwright & Co. Reiterates Harmony Biosciences Holdings (HRMY) Buy Recommendation - Nasdaq
Harmony Biosciences reports positive results for pitolisant GR formulation By Investing.com - Investing.com Nigeria
HC Wainwright Reiterates Buy Rating for HRMY, Maintains Price Ta - GuruFocus
Needham Reiterates Buy Rating on HRMY with Unchanged Price Targe - GuruFocus
Harmony Biosciences to Submit NDA for Narcolepsy Treatment Following Trial Results - marketscreener.com
Harmony Biosciences (HRMY) Advances with New Pitolisant Formulat - GuruFocus
Harmony Biosciences reports positive results for pitolisant GR formulation - Investing.com
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation - Lelezard
Harmony Biosciences reports positive pitolisant bioequivalence study results - StreetInsider
Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) Post Mgmt Meet - StreetInsider
CFO Kapadia Files To Sell 3,427 Of Harmony Biosciences Holdings Inc [HRMY] - TradingView
Is Harmony Biosciences Holdings Inc. stock supported by strong cash flows2025 Technical Overview & Smart Investment Allocation Tips - newser.com
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 28% Share Price Climb - simplywall.st
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence - BioSpace
What insider trading reveals about Harmony Biosciences Holdings Inc. stockEarnings Growth Report & Low Risk Entry Point Guides - newser.com
Harmony Advances First Human Study of Orexin 2 Agonist - Sleep Review
0.14%
0.34%
大文字化:
|
ボリューム (24 時間):